the inventive concept described herein is based in part on the surprising observation that a muramyl dipeptide cross - linked into a microparticle ( mdp - microparticle ) contains dna fragments , probably of bacterial origin , which may explain a further surprising observation that the microparticle is capable of selectively targeting and activating several different immune cell subsets that are central to induction of a broad range of innate and adaptive anti - neoplastic immune responses . this novel mdp - microparticle comprising dna fragment ( s ) will be referred to herein as “ mdp / dna - microparticle ”. whereas the mdp / dna - microparticle compositions of the present invention are themselves effective in targeting and activating the relevant components of the immune system to aid in destructions of neoplastic cells , the efficacy of the microparticle compositions can be further enhanced and focused by certain ligands that can be coupled to the surface of the microparticles . the activation of innate anti - tumour mechanisms by immunostimulatory compounds is now well established as a therapeutic approach for the treatment of cancer . whilst natural killer ( nk ) cells play a central role in tumor cell immunosurveillance and destruction , nkt , myeloid and plasmocytoid dendtritic cells as well as monocyte / macrophages represent additional non - redundant arms of innate anti - tumor immunity together these subsets kill tumor targets by several mechanisms which include granzyme , perforin , fas - fasl , trail and tnf - α . as well as having direct anti - tumour activity , these cell subsets also underpin the adaptive immune response , which may lead to the development of autologous tumour - specific immunity in the presence of exogenous or endogenous tumour antigen . another feature associated with particular immunostimulants is their potential to trigger a range of innate and adaptive anti - tumour mechanisms as well as reconstitute the immune system following the deleterious effects of irradiation and chemotherapy . the importance of the adaptive wing of the immune system in containing tumor growth is supported by animal studies and various observations in humans . these include increased prevalence of certain tumors following immunosuppression as well as the demonstration , that the presence of intralesional t cells is correlated with improved clinical outcome in various solid tumors . in particular in colon carcinoma , the presence of cd8 + t cells within the tumor microenvironment was significantly associated with a better survival in several studies . t cell responses against specific tumor - associated antigens ( taa ) are frequently detected in the peripheral blood of tumor patients of various histiotypes including colorectal cancer , melanoma , acute myeloid leukemia , breast cancer , neuroblastoma , and head and neck cancer . data from selected single patients suggest a favorable clinical course in patients with peripheral , spontaneous taa - directed t cells . taa - directed t cell responses can reliably be induced using various vaccination approaches . several recent reports have found a correlation between induction of a taa - directed t cell response by vaccination and clinical response . preliminary data also suggest a possibly favorable clinical effect of vaccine - induced t cells in adjuvant vaccination . spontaneous t cell responses against taas including cea , ep - cam , or her - 2 / neu have been demonstrated in peripheral blood of approximately 25 % of colorectal cancer patients . these cells were identified in functional t cell assays by antigen - induced ifnγ production . more detailed analyses in some samples revealed a cd3 + cd8 + ifnγ + cd69 + cd45ra + phenotype , indicative of an effector t cell subset that is able to directly mediate tumor cell lysis . spontaneous taa - specific t cells with the potential of effector cells should be capable of destroying tumor cells and thereby lead to elimination of residual disease or prevent tumor progression . in one embodiment the present invention contemplates use of the mdp / dna - microparticles in conjunction with one or more taas which are likely to elicit protective immune responses in a mammal , in the form of a vaccine for treating or preventing cancers . the taa may be co - administered with the mdp / dna - microparticle , in which case it is preferred that the taa is conjugated to the surface of the microparticle , or it may be administered sequentially in any order . the mdp / dna - microparticle compositions of the present invention can deliver cancer vaccine candidates including autologus tumor vaccines , and vaccines comprised of cea , ca19 - 9 , ca125 , ep - cam , her - 2 / neu , melanoma antigen gm2 , thereby permitting prophylaxis against and treatment of a variety of neoplastic diseases . in addition , the mdp / dna - microparticle compositions of the present invention can be used to treat an already existing neoplastic disease or to accompany conventional cancer treatments . the compositions of the present invention can completely or partly avoid the considerable disadvantages associated with conventional cancer treatments . some of the advantageous physico - chemical properties of the mdp / dna - microparticle of the present invention are resistance to treatment with pepsin and extremes of ph and denaturing conditions . in particular , the mdp / dna - microparticle is resistant to a ) treatment with pepsin at ph 3 . 5 , b ) a ph of less than 1 and greater than 11 at ambient temperature and c ) denaturing conditions in 6 m urea or 6 m guanidine hydrochloride while not wishing to be bound by any particular theory as to how the present invention works , applicant believes that the ability of the mdp / dna - microparticle to treat a broad spectrum of tumours arises from the demonstrable activation of natural killer cells ( nk ) and natural killer t cells ( nkt ) mediated by the establishment of myeloid and plasmacytoid dendritic cells crosstalk and up - regulation of cytokine production and receptor modulation . this in turn is thought to be mediated by the particular structure and composition of the microparticle , more particularly the presence of bacterial deoxyribonucleic acid within the structure of the microparticle . such stimulatory activity is advantageous as nk and nkt cells have been shown to play a role in controlling metastatic spread of certain neoplastic diseases following surgical removal of a solid tumour . the invention will now be more particularly described with reference to non - limiting examples . the in vitro and in vivo models used herein to demonstrate the invention are selected on the basis of their accepted ability to show anti - neoplastic activity of tested compositions . a multiple repeat of muramyl dipeptide ( mdp ) isolated from propionibacterium acini , formed the core structure of the mdp / dna - microparticle carrier complex of this example . the chemical composition of the preferred monomeric subunit is as shown below . mdp has well known immunostimulatory properties , which have been extensively evaluated in studies designed to determine its effect on increasing immune function . to date , both mdp isolated from natural sources and synthetic mdp have been associated with significant toxicity when administered to mammals . this toxicity has limited the effectiveness of mdp as an adjuvant . a method for the isolation of mdp and associated bacterial dna fragments , free from toxic components , is provided herein . propionibacterium acnes was grown to a mid - stationary growth phase and washed to remove contaminants of bacterial culture origin employing techniques well known to those in the art . hydrophobic components contained in the cell walls and cytoplasm were sequentially extracted by successive washes with increasing concentrations of ethanol / isopropanol / water ( 10 %: 10 %: 80 %, 25 %: 25 %: 50 % and 40 %: 40 %: 20 %) at elevated temperatures . the isopropyl alcohol is then removed with successive washes with decreasing concentrations ( 80 %, 50 %, 40 % and 20 %) of ethanol at elevated temperatures . the resulting mdp / dna - microparticle is then suspended in 6m guanidine - hcl and then washed into water for irrigation and its concentration measured by relating its absorbance at 540 nm to the absorbance of turbidity standards . the concentration of the mdp / dna - microparticle was adjusted to 10 mg / ml for storage and later use . analysis of this preparation demonstrated muramyl dipeptide extensively crosslinked with bacterial dna in a microparticle size predominantly in the range of 1 to 3 microns . the mdp / dna - microparticles contain muramic acid with amino - linked l - alanine - d - isoglutamine dipeptide and bacterial dna fragments as the bioactive component . such a microparticle can be isolated from natural sources , as above , or synthesized using well - known synthetic procedures ( for example , liu g . ; zhang s .- d . ; xia s .- q . ; ding z .- k . bioorganic and medicinal chemistry letters , 10 ( 12 ), 2000 , pp . 1361 - 1363 ( 3 ); schwartzman s . m ., ribi e ., prep biochem . 1980 ; 10 ( 3 ): 255 - 67 ; ohya et al . journal of bioactive and compatible polymers , 1993 ; 8 : 351 - 364 ). the mdp / dna - microparticles generated by the present methods can have a broad range of sizes ( for example , 0 . 011 - 30 microns ) but the preferred size is in the range of 0 . 5 - 3 microns . the attachment of ligands and immunogens to mdp / dna - microparticle can be accomplished employing reductive amination . those skilled in the art will recognize that stable carbonyl groups can be produced on mdp / dna - microparticle , carbohydrate containing ligands / immunogens or on a dextran , polyethelene glycol or mannin bridge by oxidation of carbohydrate with sodium metaperiodate . this results in the formation of stable carbonyl groups ( aldehyde ) which in turn react spontaneously with amino groups present on certain tlr ligands and immunogens to form schiff &# 39 ; s base intermediates . the addition of sodium cyanoborohydride to a reaction in which schiff &# 39 ; s base formation has occurred results in complete reduction of the labile schiff &# 39 ; s base intermediate to a chemically stable bond ( see figure below ). unlike sodium borohydride , sodium cyanoborohydride is sufficiently mild to avoid adversely reducing aldehydes to non reactive hydroxyls . this methodological approach is described in current protocols in immunology ; series editor : richard coico ( cornell university ) published by john wiley & amp ; sons , inc . an example of the method employed is as follows : mdp / dna - microparticle ( 20 mg ) in 20 % ethanol is pelleted by centrifugation , resuspended in and extensively washed with water . the mdp / dna - microparticle is then pelleted and resuspended at a concentration of 50 mg of the mdp / dna - microparticle / ml in sodium metaperiodate ( 0 . 05 - 0 . 5m ) and an oxidation reaction is carried out for 1 hour at room temperature . following activation with sodium metaperiodate , the mdp / dna - microparticle suspension is pelleted by centrifugation , resuspended in and extensively washed with water . the concentration of the sodium metaperiodate and the reaction time can be varied to regulate the number of activated sites produced within the mdp / dna - microparticle , ligand , immunogen or the like during oxidation . an activated mdp / dna - microparticle should react with and covalently attach at least one molecule of the subject immunogen or ligand per mdp / dna - microparticle , preferably 10 - 100 molecules of subject peptide or ligand per mdp / dna - microparticle and most preferably 100 to 1000 subject peptide or ligand per mdp / dna - microparticle . for a highly activated mdp / dna - microparticle preparation a final concentration of 0 . 5 m sodium metaperiodate is used and the oxidation reaction is carried out for one hour . a preferred concentration of sodium metaperiodae is between 5 and 30 mm . following sodium metaperiodate oxidation the mdp / dna - microparticle is then pelleted and washed extensively to removal the sodium metaperiodate . the activated mdp / dna - microparticle is then re - suspended in the desired immunogen or ligand ( for example tlr9 or nod2 at ≧ 1 mg / ml at a 20 : 1 w / w ratio ) in sodium bicarbonate buffer ( 0 . 1 m ph 9 . 5 ) and incubated ( ambient temperature ) for 18 - 24 hours . the reactants are centrifuged and the pellet that now contains the immunogen / ligand linked to the mdp / dna - microparticle through an intermediate schiff &# 39 ; s base is reduced forming a stable covalent linkage between the mdp / dna - microparticle and the immunogens / ligands . numerous reducing agents can be employed and sodium borohydride is an example of a reducing agent typically used for this purpose . following reduction of the schiff &# 39 ; s base the mdp / dna - microparticle - immunogen / ligand conjugate is pelleted , washed and resuspended in the desired vaccine buffer at the desired immunogen / ligand concentration . the covalent attachment of immunogen or ligand , if used , to the mdp - dna microparticle can also be made through bi - functional cross linkers . dma , dmp and dms ( shown below ) are water soluble , membrane permeable , homobifunctional imidoester cross - linkers . the imidoester functional group is one of the most specific acylating groups available for the modification of primary amines and has minimal cross reactivity toward other nucleophilic groups in proteins / ligands . in addition , the imidoamide reaction product does not alter the overall charge of the protein , potentially retaining the native conformation and activity of the protein / ligand . conjugation of protein / ligand is achieved through a two step reaction where mdp / dna - microparticle is first incubated with the desired imidoester crosslinker chosen from the three shown below based on spacer arm length required to avoid steric hinderance . the free amino groups present on mdp / dna - microparticle are first saturated by incubation with a 20 fold molar excess of the cross - linker dissolved in 0 . 2 m triethanolamine , ph 8 . 0 ( reaction buffer ). the reaction mixture is incubated at room temperature for 30 minutes and excess crosslinker is removed from the activated mdp / dna - microparticle by centrifugation and washing ( 3 ×) with reaction buffer . activated mdp / dna - microparticle is resuspended in reaction buffer containing the desired ligand . the reaction mixture is incubated at room temperature for 1 - 2 hours and mdp / dna - microparticle - ligand conjugate is pelleted , washed (× 3 ) with saline glycine buffer ( 0 . 05 m glycine ph 6 . 5 , nacl 0 . 9 %) and bioactivity is measured by cytokine induction assays . similar proportions of microparticle and immunogen / ligand are used as outlined above for reductive animation attachment method . it should be noted , although without limitation to the mechanism of action , that the mdp / dna - microparticle - immunogen / ligand composition likely affects immunogenicity by influencing preferential cell uptake , protein half - life , and antigen presentation through mhc immunological events . when immunization with more than one subject immunogen / ligand is desired , a cocktail of subject immunogen / ligand mdp / dna - microparticle conjugates can be prepared by mixing individual conjugates at ratios to optimize immunogenicity of each subject peptide introduced in the cocktail . in this configuration sufficient immunogen is available on each microparticle conjugate ( 100 - 1000 immunogens - ligands / microparticle ) to enhance antigen presentation by a single antigen - presenting / responder cell . immunogenicity / activity of the subject immunogen / ligand can be optimized by adjusting both the number of subject peptides per mdp / dna - microparticle carrier and when desired the ratio of immunogens within a vaccine cocktail to achieve the desired immune response . in this configuration , antigen processing by the antigen presenting cell results in a high density , usually more than 100 and most frequently more than 500 peptides , presented at the cell surface of the antigen - presenting cell through mhc interactions . other methods for attachment may employ maleimide conjugation chemistries . maleimide linkage may be performed using a sulfo modified sulfosuccinimidyl - 4 - cyclohexane - 1 - carboxylate according to standard protocols using sulfo - smcc ( pierce ) or other linkers suitable for sulfhydryl linkage . internalisation of fluorescently labelled mdp / dna - microparticle ( mis ) by peripheral blood monocytes , plasmocytoid ( pdc ) and myeloid ( mdc ) dendritic cells whole blood was incubated with 50 , 25 , 10 or 1 μg / ml of alexafluor 488 ( invitrogen ) labelled - mdp / dna - microparticle ( made in house using standard protocol supplied with reagent ) and incubated for 30 minutes at 37 ° c . flow cytrometric analysis of monocytes , plasmocytoid and myeloid dc was performed following cell labelling with a panel of fluorescent antibodies ( becton dickinson ). cells were gated based on cd45 , bdca - 1 , bdca - 2 , lineage marker and cd14 expression . the % of each subset that internalised af488 - mdp / dna - microparticle ( mis ) is shown in fig1 . mdp / dna - microparticle ( mis ) stimulation of human pbmc results in the production of anti - neoplastic cytokines ifn - α , tnf - α and il - 12p70 human pbmc ( 10 6 / ml ) were cultured with lps ( e coli ; 100 ng / ml ), pma ( 1 nm )+ ionomycin ( 100 ng / ml ) ( both assay negative controls for ifn - α production ) or mdp / dna - microparticle ( 10 and 1 μg / ml ) for 96 hours . supernatants were assayed for secreted ifn - α using flow cytometric cytokine bead array technology according to the manufacturers &# 39 ; standard protocols ( bender medsystems ). fig2 shows that mdp / dna - microparticle induces ifn - α in a dose - responsive manner . mdp / dna - microparticle ( mis ) induction of ifn - α is preferentially mediated by plasmocytoid dendritic cells , which are known to be the primary cellular sensor for nucleic acid human pdcs were purified from pbmcs using magnetic bead selection of bdca - 2 + cells to high purity and viability ( fig3 a ). sorted pdc were cultured at 2 . 6 × 10 5 cells / ml in the presence of recombinant human gm - csf ( 200 u / ml ) and il - 3 ( 10 ng / ml ) and either with no stimulus , heat - killed streptococcus aureus ( hksa ; 1 × 10 8 particles / ml ), lps ( e coli ; 100 ng / ml ), monomeric mdp ( 20 μg / ml ), tlr9 type c ligand ( cpg odn m362 ; 0 . 1 μm ) or mdp / dna - microparticle ( 10 μg / ml ) for 24 hours . human pbmc ( 10 6 / ml ) cultures were initiated in parallel . supernatants were harvested at 96 hours and assayed for ifn - α content using flow cytometry cytokine bead array methodology . as can be seen in fig3 b , enrichment for pdc results in a substantial increase in the amount secreted ifn - α following mdp / dna - microparticle stimulation as compared to that detected in supernatants from mdp / dna - microparticle stimulated pbmc . induction of monocyte tnfα production following 22 - hour stimulation with mdp / dna - microparticle ( mis ) human pbmc ( 10 6 / ml ) were cultured with mdp / dna - microparticle at 20 , 10 , 5 and 1 μg / ml for 22 hours . a protein transport inhibitor ( brefeldin a ) was added for the last 6 hours of the culture to enable cytokine accumulation . cells were labelled with fixable violet live / dead stain ( invitrogen ), washed and subsequently fixed / permeabilised using cytofix / cytoperm ( becton dickinson ), followed by labelling with anti - tnf - α - apc - cy7 monoclonal antibody ( becton dickinson ). viable monocytes were identified based on live / dead dye exclusion combined with fsc - ν - high ssc gating . in fig4 the proportion of gated viable monocytes expressing tnf - α at all concentrations of mdp / dna - microparticle was determined . the largest proportion of viable monocytes expressing tnf - α is 73 . 8 % at 20 μg / ml of mdp / dna - microparticle . enhancement of human pbmc nk early activation antigen expression following stimulation with mdp / dna - microparticle ( mis ) human pbmc ( 10 6 / ml ) were cultured with mdp / dna - microparticle at 10 , 5 and 1 μg / ml . known nk cell - activating agent , il - 2 ( 500 u / ml ) served as assay positive control . following 18 hr culture , pbmc nk activation status was determined by flow cytometric analysis of fluorescent antibody ( cd3 , cd56 and cd69 ; becton dickinson ) labelled cells . viable nk cells were gated based on propidium iodide − cd3 − cd56 + phenotype and cd69 activation antigen expression was determined on the gated population . the region indicating the percentage of nk cells expressing cd69 in the presence or absence of mdp / dna - microparticle is shown in fig5 . ifnγ , gm - csf , and tnf - α production by purified nk and nkt cells following a 40 - hour stimulation with mdp / dna - microparticle ( mis ) human cd56 + cells were purified from whole blood to 99 % purity using macs positive selection beads ( miltenyi ), which isolates both nk ( cd56 + cd3 − ) and nkt cells ( cd56 + cd3 + ). purified cells were then cultured ( 7 . 5 × 10 5 / ml ) with no stimulus , il - 2 ( 500 u / ml ), il - 12 ( 50 ng / ml ), or mdp / dna - microparticle ( 20 , 10 , 5 and 1 μg / ml ) for 40 hours . supernatants were assayed for ifn - γ , tnf - α , and gm - csf content using flow cytometry cytokine bead array methodology according to manufacturers &# 39 ; standard protocol ( bender medsystems ). as can be seen in fig6 , mdp / dna - microparticle clearly stimulates the production of the anti - neoplastic cytokines ifnγ and tnfα , as well as gm - csf which may help the body build an effective immune response to kill cancer cells . mdp / dna - microparticle ( mis ) stimulation of purified nk and nkt cells resulting in an up - regulation of the release of tumouricidal quantities of fas - l human cd56 + cells were purified from whole blood to 99 % purity using macs positive selection beads , which isolates both nk ( cd56 + cd3 − ) and nkt cells ( cd56 + cd3 + ) according to manufacturers standard protocol ( miltenyi ). purified cells were then cultured at 10 6 / ml with no stimulus , known nk activating agents il - 2 ( 500 u / ml ), il - 12 ( 50 ng / ml ), poly i : c ( 50 μg / ml ) or with mdp / dna - microparticle ( 20 , 10 , 5 , 1 , 0 . 5 and 0 . 1 μg / ml ). following a 20 hour culture , cell - free supernatants were harvested and assayed for soluble fas - l using flow cytometry bead array methodology according to manufacturers &# 39 ; protocol ( becton dickinson ) as shown in fig7 a . macs purified cd56 + cells at 10 6 / ml were then cultured for 69 hours with il - 2 ( 500 u / ml ), il - 12 ( 50 ng / ml ), poly i : c ( 50 μg / ml ) or mdp / dna - microparticle ( 10 and 1 μg / ml ). cell - free supernatants were harvested and tested for fas - mediated cytotoxcity by 4 hour culture of did ( invitrogen ) fluorescently labelled fas sensitive daudi tumour targets with ½ or ¼ diluted supernatants . daudi cell killing was determined by flow cytometric determination of viability dye ( propidium iodide ; invitrogen ) uptake ( live / dead discrimination ) of gated , fluorescent tumour targets . as can be seen in fig7 b , the mdp / dna - microparticle stimulated cell - culture supernatants produced a greater percentage kill of daudi cells than supernatants from cells stimulated with il - 2 , il - 12 or poly i : c . mdp / dna - microparticle ( mis ) mediated enhancement of human pbmc spontaneous killing activity against nk sensitive k562 ( erythroleukemia ) and du - 145 ( prostate ) as well as fas - l sensitive daudi ( burkitt &# 39 ; s lymphoma ) and t47d ( breast ) tumour cell targets human pbmcs ( 10 6 / ml ) were cultured with mdp / dna - microparticle at 20 and 5 μg / ml . known nk / nkt cell - activating agents , il - 2 ( 500 u / ml ), il - 12 ( 50 ng / ml ) and tlr3 ligand , poly i : c ( 50 μg / ml ) served as assay positive controls . following a 46 hour culture , activated pbmcs were then washed into fresh medium and tested for cytotoxicity against fluorescently labelled ( did ; invitrogen ) tumour target cells at an effector : target ratio of 100 : 1 . tumour cell killing was determined after 4 hours by flow cytometric determination of propidium iodide viability dye uptake ( live / dead discrimination ) of gated , fluorescent tumour targets . from fig8 it can be seen that mdp / dna - microparticle stimulation enhances human pbmc spontaneous killing activity against nk sensitive k562 ( erythroleukemia ) and du - 145 ( prostate ) as well as fas - l sensitive daudi ( burkitt &# 39 ; s lymphoma ) and t47d ( breast ) tumour cell targets . enhancement of purified human nk spontaneous killing activity following stimulation with mdp / dna - microparticle ( mis ) human cd56 + cells were purified from whole blood to 99 % purity using macs positive selection beads , which isolate both nk ( cd56 + cd3 −) and nkt cells ( cd56 + cd3 + ) according to manufacturers standard protocol ( miltenyi ). purified cells were then cultured at 7 . 5 × 10 5 / ml with no stimulus , known nk activating agents il - 2 ( 500 u / ml ), il - 12 ( 50 ng / ml ), ifn - α ( 500 and 2000 u / ml ), poly i : c ( 50 μg / ml ) or with mdp / dna - microparticle ( 40 , 20 , 10 and 5 μg / ml ). following a 40 hour culture , stimulated nk cells were washed into fresh medium and tested for cytotoxicity against fluorescently labelled ( did ; invitrogen ) nk sensitive k562 tumour targets at effector : target ratios of 5 : 1 , 2 : 1 and 1 : 1 . tumour cell killing was determined after 4 hours by flow cytometric analysis of viability dye uptake ( propidium iodide ) of gated , fluorescent k562 targets . from fig9 it can be seen that tumour cell killing is greater at all ratios tested when nkcells are stimulated with mdp / dna - microparticle . mdp / dna - microparticle ( mis416 ) has anti - metastatic activity as a stand - alone agent or co - therapy in metastatic breast cancer and lewis lung carcinoma models tumours were established from cultured breast cancer 4t1 cells which were injected in the mammary fat pad ( balb / c ; female ). at 48 hrs post inoculation , a single 250 μg bolus of mdp / dna - microparticle was administered via i . v delivery . the numbers of surface lung metastases were determined at study termination ( day 23 ) ( fig1 a ). for analysis of statistical significance * denotes statistical significance relative to control ( p ≦ 0 . 044 ; unpaired one - tailed t - test ). female c57b1 / 6 mice ( 10 per group ) were injected with 10 6 lewis lung carcinoma cells intravenously ( fig1 b ). on day 4 post injection of carcinoma cells , therapy was initiated according the following treatment schedule ( i ) no treatment ( ii ) mdp / dna - microparticle ( mis416 ) alone , 50 μg ( iii ) 4gy lung irradiation on day 5 , 6 and 7 ( iv ) 50 μg mdp / dna - microparticle ( mis416 ) plus 4gy lung irradiation on day 5 , 6 and 7 . mdp / dna - microparticle ( mis416 ) was administered in saline via i . v route . on day 14 , lung colonies were removed and assessed for lung colonies . for analysis of statistical significance * denotes statistical significance relative to control ( p & lt ; 0 . 0006 ; unpaired one - tailed t - test ) and * denotes significance relative to each individual therapy ( p & lt ; 0 . 0001 ). these studies demonstrate that mdp / dna microparticle therapy inhibits the formation of spontaneous lung metastases that arise from unrelated tumour mass occurring at an anatomically distant site . these studies also demonstrate that mdp / dna - microparticle therapy is inhibitory for the growth of lung metastases when administered following early , direct establishment of metastases in the lung . moreover , there is demonstrable synergy between local radiotherapy and mdp / dna - microparticle co - therapy for inhibition of lung metastases growth . this indicates that a combinatorial anti - neoplastic regimen that includes innate immunostimulation can lead to an improved therapeutic outcome . mdp / dna - microparticle ( mis416 ) therapy induces a cellular immune response towards endogenous tumour associated antigen ( ova ) in a b16 - ova therapeutic vaccine model syngeneic c57 / b16 mice were implanted with b16 - ova cells ( 1 × 10 6 per mouse ) and tumours were allowed to grow until 4 - 5 mm diameter . mdp / dna - microparticle was administered on day 8 by i . v delivery of a single 50 μg bolus . on day 20 following therapy , spleens were excised and antigen restimulation assays were performed against el4 - mart and b16 - ova tumour cells as well as soluble ova peptide ( fig1 ). elispot quantitation of ifn - γ secreting cells was performed as a measure of ifn - γ expressing cytotoxic cd8 + t cells . ova tetramer binding assays have confirmed the increased frequency of splenic ova specific cd8 + t cells in this model . mdp / dna - microparticle therapy significantly increased the frequency of ifn - γ ova - specific t cells relative to non - treated or irrelevant controls (* denotes statistical significance relative to control ( p & lt ; 0 . 005 ; unpaired one - tailed t - test ). these studies demonstrate that mdp / dna - microparticle therapy has immunostimulatory , adjuvant properties that support the induction of adaptive immune responses directed preferentially towards a tumour associated antigen . this is desirable , since these types of responses lead to the development of adaptive , protective immunity towards autologous tumours preventing the re - occurrence of primary and / or metastatic disease . vaccination with ova - mdp / dna - microparticle ( mis416 ) immunoconjugates induces peripheral expansion of adoptively transfered ot - 1 cd8 + cells and induction of anti - tumour immunity in a prophylactic tumour vaccine model ( a ) syngeneic purified cd8 + ot - i cells ( 10 3 ) were adoptively transferred to groups of mice ( c57 / b16 ; n = 10 ) via i . v delivery followed by i . v immunization with either 25 μg ova , 25 μg ova - mdp / dna - microparticle ( mis416 ) immunoconjugate or 25 μg ova mixed with 200 ng α - galactoceramide ( positive control for i . v immunization for th1 responses ). peripheral blood was sampled at various time points up to day 35 post immunization . the expansion of ot - i cells was determined using flow cytometric analysis for t cells with a cd8 + cd45 . 1 + vα2 + phenotype ( ot - i specific ) ( fig1 a ). on day 36 post immunizations , 10 6 b16 - ova tumour cells were injected s . c . and tumour growth was monitored ( fig1 b ). these results demonstrate that pre - treatment with mdp / dna - microparticle - tumour antigen immunoconjugates induces protective th1 type immune responses . these responses are associated with tumour rejection . treatment with mdp / dna - microparticle ( mis416 ) in vitro and in vivo leads to the production of growth factors that are central to immune replenishment and functional reconstitution healthy donor pbmc and incubated for 6 hours at 37 degree centigrade with 5 μg / ml mdp / dna - microparticle . non - stimulated cell cultures were established as a control . whole rna from the pbmc was extracted using roche rna extraction kit and cdna was synthesized also using roche cdna synthesis kit . this cdna was put with primers coated in individual wells in a 96 well format . real time quantitative pcr was conducted for a range of human genes and the fluorescence was read . the fold changes calculated for each gene by determining the differential expression between an un - stimulate and a stimulated fraction . an increased fold change is reflective of an upregulation . the upregulation of il - 3 , il - 7 and csf2 ( gmcsf ) was detected ( fig1 a ). peripheral blood serum was harvested at 24 and 48 hours following i . v administration of a single 500 μg bolus of mdp / dna - microparticle . the concentration of il7 and gmcsf was determined using flow cytometry cytokine bead array methodology carried out according to manufacturers &# 39 ; standard protocol ( becton dickinson ) ( fig1 b ). although the invention has been described with reference to certain preferred embodiments and examples it will be understood that variations in keeping with the spirit of the invention and the disclosure provided herein are also contemplated .
the present invention is concerned with immunostimulant compositions , in particular compositions comprising microparticulate form of murmyl dipeptide , and their use in the treatment of neoplastic disease .